	SEQUENCE LISTING									
	(1) GENERAL INFORMATION:									
	(i) APPINICANT: Mukherjee, Ranjan									
5	(ii) TITLE OF INVENTION: Human Peroxisome Proliferator Activated Receptor γ									
10	(iii) NUMBER OF SEQUENCES: 2									
	(iv) CORRESPONDENCE ADDRESS:									
15	(A) ADDRESSEE: Lyon & Lyon (B) STREET: 633 West Fifth Street (C) CITY: Los Angeles (D) STATE: California (E) COUNTRY: USA (F) ZIP: 90071									
20	(v) COMPUTER READABLE FORM:									
	(A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb									
`	(B) COMPUTER: IBM compatible									
/	(C) OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)									
25	(D) SOFTWARE: WordPerfect (Version 5.1)									
	(vi) CURRENT APPLICATION DATA:									
30	(A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION:									
	(viii) ATTORNEY/AGENT INFORMATION:									
35	(A) NAME: Warburg, Richard J. (B) REGISTRATION NUMBER: 32,327 (C) REFERENCE/DOCKET NUMBER: 210/100									
	(ix) TELECOMMUNICATION INFORMATION:									
40	(A) TELEPHONE: (213) 489-1600 (B) TELEFAX: (213) 955-0440 (C) TELEX: 67-3510									

210/100 PATENT

54

# (2) INFORMATION FOR SEQ ID NO: 1:

5

# (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: (B) TYPE: nucleic acid

1641

(C) STRANDEDNESS: single (D) TOPOLOGY: linear

# (xi) SEQUENCE DESCRIPTION : SEQ ID NO: 1:

	(XI)	SEQUENCE D	ESCRIPTION	: SEQ ID NO	: т:	
10	GAATTCCGGA	CCCTCAACAC	CACTCCCTCT	TAGCCAATAT	TGTGCCTATT	50
	GCCATACTAG	TCTTTGCGCC	TCCGAAGCAG	CGGTGGCCTA	${\tt GCCCTACTAG}$	100
	TCTCAATCTC	CAACATATAT	CGOCTAGAC	TACGTACATA	ACCTAAACCT	150
	ACTCCAATGC	TAAAACTAAT	CGTCCCTTTT	CTCAAACGAG	AGTCAGCCTT	200
	TAACGAAATG	ACCATGGTTG	ACACAGAGAT	GCCATTCTGG	CCCACCAACT	250
15	TTGGGATCAG	CTCCGTGGAT	CTCTCCGTAA	TGGAAGACCA	CTCCCACTCC	300
	TTTGATATCA	AGCCCTTCAC	TACTGTTGAC	TTCTCCAGCA	TTTCTACTCC	350
	ACATTACGAA	${\tt GACATTCCAT}$	TCACAAGAAC	AGATCCAGTG	GTTGCAGATT	400
	ACAAGTATGA	CCTGAAACTT	CAAGAGTACC	AAAGTGCAAT	CAAAGTGGAG	450
	CCTGCATCTC	CACCTTATTA	TTCTGAGAAG	ACTCAGCTCT	ACAATAAGCC	500
20	TCATGAAGAG	CCTTCCAACT	CCCTCATGGC	AATTGAATGT	CGTGTCTGTG	550
	GAGATAAAGC	${\tt TTCTGGATTT}$	CACTATGGAG	TTCATGCTTG	TGAAGGATGC	600
	${\tt AAGGGTTTCT}$	TCCGGAGAAC	AATCAGATTG	AAGCTTATCT	ATGACAGATG	650
	TGATCTTAAC	TGTCGGATCC	ACAAAAAAAG	TAGAAATAA	TGTCAGTACT	700
	${\tt GTCGGTTTCA}$	GAAATGCCTT	GCAGTGGGGA	TGTCTCATAA	TGCCATCAGG	750
25	${\tt TTTGGGCGGA}$	TGCCACAGGC	CGAGAAGGAG	AAGCTGTTGG	CGGAGATCTC	800
	CAGTGATATC	GACCAGCTGA	ATCCAGAGTC	CGCTGACCTC	cheecccie	850
	CAAAACATTT	GTATGACTCA	TACATAAAGT	CCTTCCCGCT	GACCAAAGCA	900
	AAGGCGAGGG	CGATCTTGAC	AGGAAAGACA	ACAGACAAAT	CACCATTCGT	950
	TATCTATGAC	ATGAATTCCT	TAATGATGGG	AGAAGATAAA	ATCAAGTTCA	1000
30	AACACATCAC	CCCCTGCAG	GAGCAGAGCA	AAGAGGTGGC	CATCCGCATC	1050
	TTTCAGGGCT	GCCAGTTTCG	CTCCGTGGAG	GCTGTGCAGG	AGATCAÇAGA	1100
	GTATGCCAAA	AGCATTCCTG	GTTTTGTAAA	TCTTGACTTG	AACGACCAAG	1150
	TAACTCTCCT	CAAATATGGA	GTCCACGAGA	TCATTTACAC	AATGCTGGCC	1200
	TCCTTGATGA	ATAAAGATGG	GGTTCTCATA	TCCGAGGGCC	AAGGCTTCAT\	1250
35	GACAAGGGAG	TTTCTAAAGA	GCCTGCGAAA	GCCTTTTGGT	GACTTTATGG	£300
	AGCCCAAGTT	TGAGTTTGCT	GTGAAGTTCA	ATGCACTGGA	ATTAGATGAC	1850
	AGCGACTTGG	CAATATTTAT	TGCTGTCATT	ATTCTCAGTG	GAGACCGCCC	14/00
	AGGTTTGCTG	AATGTGAAGC	CCATTGAAGA	CATTCAAGAC	AACCTGCTAC	1450

55 210/100 PATENT

AAGCCCTOGA GCTCCAGCTG AAGCTGAACC ACCCTGAGTC CTCACAGCTG 1500
TTTGCCAAGC TGCTCCAGAA AATGACAGAC CTCAGACAGA TTGTCACGGA 1550
ACACGTGCAG CTACTGCAGG TGATCAAGAA GACGGAGACA GACATGAGTC 1600
TTCACCCGCT CCTGCAGGAG ATCTACAAGG ACTTGTACTA G 1641

5

#### (2) INFORMATION FOR SEQ ID NO: 2:

#### (i) SEQUENCE CHARACTERISTICS:

10

25

35

- (A) DENGTH:
- 494
- (B) TYPE:
- amino acid
- (C) STRANDEDNESS:
- single
- (D) TOPOLOGY:
- linear

### (ii) MOLECULE TYPE: peptide

15 (xi) SEQUENCE DESCRIPTION : SEQ ID NO: 2

Met Leu Lys Leu Ile Val Pro Phe Leu Lys Arg Glu Ser Ala Phe
5 10 15

Asn Glu **Met** Thr **Met** Val Asp Thr Glu Met Pro Phe Trp Pro Thr 20 25 30

20 Asn Phe Gly Ile Ser Ser Val Asp Leu Ser Val Met Glu Asp His 35 40 45

Ser His Ser Phe Asp Ile Lys Pro Phe Thr Val Asp Phe Ser

Ser Ile Ser Thr Pro His Tyr Glu Asp Ile Pro Phe Thr Arg Thr
65 70 75

Asp Pro Val Val Ala Asp Tyr Lys Tyr Asp Leu\Lys Leu Gln Glu
80 85 90

Tyr Gln Ser Ala Ile Lys Val Glu Pro Ala Ser Pro Pro Tyr Tyr 95 100 105

30 Ser Glu Lys Thr Gln Leu Tyr Asn Lys Pro His Glu\Glu Pro Ser

Asn Ser Leu Met Ala Ile Glu Cys Arg Val Cys Gly Asp Lys Ala 125 130 135

Ser Gly Phe His Tyr Gly Val His Ala Cys Glu Gly Cys Tys Gly

Phe Phe Arg Arg Thr Ile Arg Leu Lys Leu Ile Tyr Asp Arg Cys
155 160

		56									210/100 PATENT				
	Asp	Deu	Asn	Cys	Arg 170	Ile	His	Lys	Lys	Ser 175	Arg	Asn	Lys	Cys	Gln 180
	Tyr	Cys	rg	Phe	Gln 185	Lys	Cys	Leu	Ala	Val 190	Gly	Met	Ser	His	Asn 195
5	Ala	Ile	Arg	Phe	Gly 200	Arg	Met	Pro	Gln	Ala 205	Glu	Lys	Glu	Lys	Leu 210
	Leu	Ala	Glu	Ile	Ser 215	Ser	Asp	Ile	Asp	Gln 220	Leu	Asn	Pro	Glu	Ser 225
10	Ala	Asp	Leu	Arg	A) a 230	Leu	Ala	Lys	His	Leu 235	Tyr	Asp	Ser	Tyr	Ile 240
	Lys	Ser	Phe	Pro	Leu 245	Thr	Lys	Ala	Lys	Ala 250	Arg	Ala	Ile	Leu	Thr 255
	Gly	Lys	Thr	Thr	Asp 260	Lys	Ser	Pro	Phe	Val 265	Ile	Tyr	Asp	Met	Asn 270
15	Ser	Leu	Met	Met	Gly 275	Glu	Asp	Lys	Ile	Lys 280	Phe	Lys	His	Ile	Thr 285
	Pro	Leu	Gln	Glu	Gln 290	Ser	Lys	Gl	Val	Ala 295	Ile	Arg	Ile	Phe	Gln 300
20	Gly	Cys	Gln	Phe	Arg 305	Ser	Val	Glu	Ala	Val 310	Gln	Glu	Ile	Thr	Glu 315
	Tyr	Ala	Lys	Ser	Ile 320	Pro	Gly	Phe	Val	1sn 325	Leu	Asp	Leu	Asn	Asp 330
	Gln	Val	Thr	Leu	Leu 335	Lys	Tyr	Gly	Val	His 340	Glu	Ile	Ile	Tyr	Thr 345
25	Met	Leu	Ala	Ser	Leu 350	Met	Asn	Lys	Asp	Gly 355	Va	Leu	Ile	Ser	Glu 360
	Gly	Gln	Gly	Phe	Met 365	Thr	Arg	Glu	Phe	Leu 370	Lys	Sar	Leu \	Arg	Lys 375
30	Pro	Phe	Gly	Asp	Phe 380	Met	Glu	Pro	Lys	Phe 385	Glu	Phe	Ala	Val	Lys 390
	Phe	Asn	Ala	Leu	Glu 395	Leu	Asp	Asp	Ser	Asp 400	Leu	Ala	Ile	Phe	Ile 405
	Ala	Val	Ile	Ile	Leu 410	Ser	Gly	Asp	Arg	Pro 415	Gly	Leu	Leu	Ash	Val 420
35	Lys	Pro	Ile	Glu	Asp 425	Ile	Gln	Asp	Asn	Leu 430	Leu	Gln	Ala	Leu	61u 435

57

210/100 PATENT Leu Gln Leu Lys Leu Asn His Pro Glu Ser Ser Gln Leu Phe Ala Lys Leu Leu Gln Lys Met Thr Asp Leu Arg Gln Ile Val Thr Glu 460 5 His Val Gln Leu Leu Gln Val Ile Lys Lys Thr Glu Thr Asp Met Ser Leu His Pro Leu Leu Gln Glu Ile Tyr Lys Asp Leu Tyr 485 490